Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.
Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B, Hallek M, Döhner H, Hillmen P, van Oers M, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T; European Research Initiative on CLL (ERIC). Pospisilova S, et al. Among authors: hillmen p. Leukemia. 2012 Jul;26(7):1458-61. doi: 10.1038/leu.2012.25. Epub 2012 Feb 2. Leukemia. 2012. PMID: 22297721 Review.
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia.
Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Döhner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ, Rai K; International Workshop on Chronic Lymphocytic Leukemia (IWCLL). Binet JL, et al. Among authors: hillmen p. Blood. 2006 Feb 1;107(3):859-61. doi: 10.1182/blood-2005-04-1677. Epub 2005 Oct 13. Blood. 2006. PMID: 16223776 Free article. Review.
The evolving role of alemtuzumab in management of patients with CLL.
Faderl S, Coutré S, Byrd JC, Dearden C, Denes A, Dyer MJ, Gregory SA, Gribben JG, Hillmen P, Keating M, Rosen S, Venugopal P, Rai K. Faderl S, et al. Among authors: hillmen p. Leukemia. 2005 Dec;19(12):2147-52. doi: 10.1038/sj.leu.2403984. Leukemia. 2005. PMID: 16239912
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.
Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, Coutre SE, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P. Rawstron AC, et al. Among authors: hillmen p. Leukemia. 2007 May;21(5):956-64. doi: 10.1038/sj.leu.2404584. Epub 2007 Mar 15. Leukemia. 2007. PMID: 17361231
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia. Hallek M, et al. Among authors: hillmen p. Blood. 2008 Jun 15;111(12):5446-56. doi: 10.1182/blood-2007-06-093906. Epub 2008 Jan 23. Blood. 2008. PMID: 18216293 Free PMC article.
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A; Hx-CD20-406 Study Investigators. Wierda WG, et al. Among authors: hillmen p. J Clin Oncol. 2010 Apr 1;28(10):1749-55. doi: 10.1200/JCO.2009.25.3187. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194866 Free PMC article. Clinical Trial.
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Wendtner CM, Hillmen P, Mahadevan D, Bühler A, Uharek L, Coutré S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA. Wendtner CM, et al. Among authors: hillmen p. Leuk Lymphoma. 2012 Mar;53(3):417-23. doi: 10.3109/10428194.2011.618232. Epub 2011 Nov 15. Leuk Lymphoma. 2012. PMID: 21879809 Clinical Trial.
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
Rawstron AC, Böttcher S, Letestu R, Villamor N, Fazi C, Kartsios H, de Tute RM, Shingles J, Ritgen M, Moreno C, Lin K, Pettitt AR, Kneba M, Montserrat E, Cymbalista F, Hallek M, Hillmen P, Ghia P; European Research Initiative in CLL. Rawstron AC, et al. Among authors: hillmen p. Leukemia. 2013 Jan;27(1):142-9. doi: 10.1038/leu.2012.216. Epub 2012 Jul 31. Leukemia. 2013. PMID: 23041722
285 results